美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

GSK plc ADRhedged

70.64

+0.84791.21%

盤後：70.55-0.0864-0.12%16:10 EDT

成交量：111

成交額：7,823

市值：70.64萬

市盈率：- -

高：70.64

開：70.55

低：70.55

收：69.79

52周最高：85.03

52周最低：55.75

股本：1.00萬

流通股本：1.00萬

量比：0.32

換手率：1.11%

股息：2.08

股息率：2.94%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

葛蘭素史克（GSK）擬斥資7.5億美元收購Chimagen旗下TCE項目全球獨家權益

118款生物藥專利懸崖將至，中國藥企業迎戰MNC最大專利懸崖

乙肝新藥中國數據出爐，但實現患者的「治癒夢」仍有門檻

每日经济新闻

功能性治癒率最高61%！乙肝新藥中國數據出爐但7500萬患者的「治癒夢」仍有門檻

每日经济新闻

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/GSKH"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"GSKH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","market":"US","secType":"STK","nameCN":"GSK plc ADRhedged","latestPrice":70.6364,"timestamp":1789588800000,"preClose":69.7885,"halted":0,"volume":111,"hourTrading":{"tag":"盘后","latestPrice":70.55,"preClose":70.6364,"latestTime":"16:10 EDT","volume":6,"amount":423.8184,"timestamp":1789589404176,"change":-0.0864,"changeRate":-0.001223,"amplitude":0},"delay":0,"changeRate":0.012149566189271809,"floatShares":10001,"shares":10001,"eps":0,"marketStatus":"已收盤","change":0.8479,"latestTime":"09-16 16:00:00 EDT","open":70.55,"high":70.6364,"low":70.55,"amount":7823,"amplitude":0.001238,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789632000000},"marketStatusCode":5,"adr":0,"exchange":"ARCA","adjPreClose":69.7885,"nav":69.73341,"aum":697403.83341,"dividendRate":0.029448,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":70.55,"preClose":70.6364,"latestTime":"16:10 EDT","volume":6,"amount":423.8184,"timestamp":1789589404176,"change":-0.0864,"changeRate":-0.001223,"amplitude":0},"volumeRatio":0.321367,"impliedVol":0.3521,"impliedVolPercentile":0.9741},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GSKH\",,,,,undefined,":{"symbol":"GSKH","floatShares":10001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.321367,"shares":10001,"dividePrice":2.0801,"high":70.6364,"amplitude":0.001238,"preClose":69.7885,"low":70.55,"week52Low":55.7526,"pbRate":"--","week52High":85.03,"institutionHeld":0,"latestPrice":70.6364,"eps":0,"divideRate":0.029448,"volume":111,"delay":0,"ttmEps":0,"open":70.55,"prevYearClose":68.2031,"prevWeekClose":66.9705,"prevMonthClose":69.8569,"prevQuarterClose":73.8574,"fiveDayClose":67.6331,"twentyDayClose":71.1955,"sixtyDayClose":71.6072},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GSKH\",params:#limit:5,,,undefined,":[{"date":"2026-06-16","symbol":"GSKH","amount":0.92785,"announcedDate":"2026-06-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-16","defaultRemindTime":1781616600000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-23","payableDate":"2026-06-16","currency":"USD","dateTimestamp":1781582400000,"payDate":"2026-06-23"},{"date":"2026-03-16","symbol":"GSKH","amount":0.36332,"announcedDate":"2026-03-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-16","defaultRemindTime":1773667800000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-23","payableDate":"2026-03-16","currency":"USD","dateTimestamp":1773633600000,"payDate":"2026-03-23"},{"date":"2025-12-16","symbol":"GSKH","amount":0.78682,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"GSK plc ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GSKH\",market:\"US\",,,undefined,":[{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.78682,"currency":"USD"},{"executeDate":"2026-03-16","recordDate":"2026-03-16","paymentDate":"2026-03-23","value":0.36332,"currency":"USD"},{"executeDate":"2026-06-16","recordDate":"2026-06-16","paymentDate":"2026-06-23","value":0.92785,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GSKH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GSKH\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667637649","title":"葛蘭素史克（GSK）擬斥資7.5億美元收購Chimagen旗下TCE項目全球獨家權益","url":"https://stock-news.laohu8.com/highlight/detail?id=2667637649","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667637649?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 18:32","pubTimestamp":1789468371,"startTime":"0","endTime":"0","summary":"金吾财讯 | 葛兰素史克（GSK）已与Chimagen Biosciences达成协议，将以高达7.5亿美元的交易总额，收购后者一款用于治疗多发性骨髓瘤的三特异性T细胞衔接器（TCE）项目的全球独家权益。根据协议，GSK将向Chimagen支付一笔首付款，并根据后续研发与商业化进展支付相应的里程碑付款。该候选药物能够同时靶向T细胞及两种肿瘤相关抗原，目前预计将于2027年正式进入I期临床试验阶段。此前，双方已就另一款处于I期临床、针对CD19/CD20的双重TCE药物CMG1A46达成合作，本次交易标志着GSK在多发性骨髓瘤及血液瘤产品线上的进一步深化布局。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306052","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4585","BK4007","GSK.UK","GSK","GSKH","BK4588","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666563124","title":"118款生物藥專利懸崖將至，中國藥企業迎戰MNC最大專利懸崖","url":"https://stock-news.laohu8.com/highlight/detail?id=2666563124","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666563124?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 15:26","pubTimestamp":1789025185,"startTime":"0","endTime":"0","summary":"BCG合伙人杜菁博士指出，未来几年全球MNC将迎来史上最大专利悬崖，有118种生物制剂将会失去相应的专利保护，涉及2340亿美元市场。然而，目前这118款即将到期分子中，只有极少数在火热开发，大量缺口有待生物类似药填补。目前来说，创新药出海还没办法完成这个闭环，但生物类似药作为先头部队做出海试验，企业风险和获益会更高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789025064363150858","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["FXH","PBPH","PJP","IHE","TMED","TRUH","BBP","159839","RSPH","MEDI","APXH","BME","JDOC","IYH","BBH","PPH","GSKH","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665937331","title":"乙肝新藥中國數據出爐，但實現患者的「治癒夢」仍有門檻","url":"https://stock-news.laohu8.com/highlight/detail?id=2665937331","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665937331?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:51","pubTimestamp":1788871868,"startTime":"0","endTime":"0","summary":"中国慢性乙型肝炎（以下简称慢乙肝）患者的“治愈”故事，正在萌芽。日前，在新加坡召开的亚洲肝病学峰会暨乙肝病毒治愈科学会议上，反义寡核苷酸（ASO）药物Bepirovirsen全球Ⅲ期研究（BWell研究）的中国人群数据完成了全球首秀：中国慢乙肝患者功能性治愈率最高可达61%，疗效与安全性趋势与全球数据一致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083868286383.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609083868286383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["GSK.UK","BK4200","GSKH","BK4585","GSK","BK4561","LU1829250122.USD","BK4588","BK4007","ASO","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665535012","title":"功能性治癒率最高61%！乙肝新藥中國數據出爐 但7500萬患者的「治癒夢」仍有門檻","url":"https://stock-news.laohu8.com/highlight/detail?id=2665535012","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665535012?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 12:14","pubTimestamp":1788581677,"startTime":"0","endTime":"0","summary":"【功能性治愈率最高61%！乙肝新药中国数据出炉 但7500万患者的“治愈梦”仍有门槛】8月31日—9月5日，在新加坡召开的亚洲肝病学峰会（AHS）暨HBV（乙型肝炎病毒）治愈科学会议上，反义寡核苷酸（ASO）药物Bepirovirsen全球Ⅲ期研究（B-Well研究）的中国人群数据完成了全球首秀：中国慢乙肝患者功能性治愈率最高可达61%，疗效与安全性趋势与全球数据一致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609053865995314.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609053865995314.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4017","BK4007","LU1223083913.SGD","BK4532","XME","SGDM","ALT","SIL","BK4599","LU1878469433.USD","BK4200","GSK.UK","CHB","GSK","GSKH","BK4588","LU1829250122.USD","LU1223082196.USD","BK4139","GDXJ","CDE","BK4561","LU1223082519.USD","ASO","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":24,"pageCount":1,"totalSize":96,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/GSKH\",params:#limit:6,delay:false,,,undefined,":[]}}